NCT05802394 (MAP-03) is a NA clinical trial of Later-line therapy in Pancreatic Cancer, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT05802394?

NCT05802394 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05802394?

Interventions in NCT05802394: Later-line therapy.

What condition does NCT05802394 study?

NCT05802394 studies Pancreatic Cancer, Locally Advanced.

Is NCT05802394 still recruiting?

NCT05802394 is currently recruiting now. Last updated 12 April 2023.

Last reviewed 2023-04-12 · How we verify

NCT05802394: MAP-03

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer

Recruiting now NA Last updated 12 April 2023

What this trial tests

NA trial testing Later-line therapy in Pancreatic Cancer in 100 participants. Currently enrolling.

Timeline

1 February 2023

Primary endpoint
1 February 2026

1 February 2030

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 February 2023
Primary completion	1 February 2026
Estimated completion	1 February 2030
Sites	1 location across China

Drugs / interventions tested

Later-line therapy — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Locally Advanced — all drugs for Locally Advanced →

Sponsor

Peking Union Medical College Hospital

Who can join

18 and older, any sex, with Pancreatic Cancer or Locally Advanced. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Japan society of clinical oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing.
Kobayashi S, Nakamura Y, Hashimoto T, Bando H, et al · · 2025 · cited 6× · PMID 39920551 · DOI 10.1007/s10147-024-02683-0
Circulating Tumor DNA as a Biomarker in Pancreatic Cancer: Clinical Applications and Challenges.
Yao G, Zhang Y, Li H, Teng L, et al · · 2026 · PMID 41718013 · DOI 10.14309/ctg.0000000000000999

Verify or expand the search:

Other trials of Later-line therapy

Trials testing the same drug.

NCT05802407 — The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer · NA · recruiting
NCT05802420 — The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer · NA · unknown

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05802394 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 12 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05802394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing